Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why

BOSTON , Dec. 12, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. Haemonetics acquired all outstanding shares of OpSens for CAD $2.90 per share in the all-cash transaction, representing a fully diluted equity value of approximately USD $255 million at the current exchange rate.

Haemonetics Corporation Completes Acquisition of OpSens Inc.

BOSTON , Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

DexCom

Integra LifeSciences Holdings

Insulet

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Integra Gains From New Product Launches, Mounting Costs Ail

Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Stryker

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

HAE vs. SYK: Which Stock Should Value Investors Buy Now?

The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Haemonetics (HAE) Loses -6.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.

Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance

Haemonetics has seen signs of growth and operational momentum after a challenging period during the pandemic. The company's fiscal year 2024 first half results were solid, increasing its appeal. Still trading at a small premium based on adjusted earnings, valuations remain somewhat demanding despite arguably a solid operating performance year to date.

Haemonetics: Solid Performance Of This Blood Play

Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon – Chief Executive Officer Stewart Strong – President of our Global Hospital business James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Group Lee Jagoda – CJS Securities Andrew Cooper – Raymond James Mike Matson – Needham & Company Michael Petusky – Barrington Research Operator Good day and thank you for standing by, and welcome to the Second Quarter 2024 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode.

Haemonetics Corporation (HAE) Q2 2024 Earnings Call Transcript

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

Financial release accessible online BOSTON , Nov. 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Baxter

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.

3 Medical Products Stocks to Consider as Earnings Approach

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth

Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands Haemonetics' Hospital product portfolio; a specialty guidewire for TAVI procedures is intriguing, but competition from established players is a concern. Closure remains an attractive business; management is launching Vascade into Europe and Japan and the business should be leveraged to ablation-driven EP procedure growth.

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Boston Scientific

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Recovery

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Haemonetics (HAE) Moves to Strong Buy: Rationale Behind the Upgrade

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

Haemonetics (HAE) Announces Agreement to Acquire OpSens

Opsens Inc shares surged 47% to $2.84 in midday trading on Tuesday after the cardiology-focused medical device company agreed to be acquired by global healthcare firm Haemonetics Corporation for C$2.90 per share in cash, representing a premium of 50% to Opsens' closing price on the Toronto Stock Exchange on Friday.  The deal values OpSens at about C$345 million, on a fully diluted equity basis.

Opsens stock soars on takeover deal with Haemonetics

Expands Haemonetics' Hospital portfolio with innovative fiber optic sensor technology for interventional cardiology Significant commercial synergies with Haemonetics' existing Vascular Closure portfolio Accelerates Haemonetics' transformational growth BOSTON , Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology.

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

BOSTON , Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 2, 2023.

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for Haemonetics Stock (HAE)